Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2021 | Novel immunotherapies for multiple myeloma

Daniel Auclair • 8 Apr 2021
ESH MM 2021
Multiple Myeloma CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel

Daniel AuClair, PhD, Multiple Myeloma Research Foundation, Norwalk, CT, outlines the use of novel agents in the treatment of multiple myeloma. Dr AuClair highlights the use of immunotherapies and the FDA approval of the first chimeric antigen receptor T-cell (CAR-T) therapy, idecabtagene vicleucel, for the treatment of patients with multiple myeloma and the potential approval of ciltacabtagene autoleucel in the future. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.

More from Daniel Auclair

2:50
IMW 2021: MRD highlights
Daniel Auclair • 11 Sep 2021
5:59
myDRUG: precision medicine in multiple myeloma
Daniel Auclair • 8 Apr 2021
5:58
What’s to come for the MMRF in 2021?
Daniel Auclair • 15 Dec 2020
2:04
How has COVID-19 affected the myeloma field?
Daniel Auclair • 15 Dec 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals